Group 1 - MIRXES-B (02629.HK) plans to globally offer 46.62 million shares, with 4.662 million shares available in Hong Kong and 41.958 million shares for international offering [1] - The subscription period is from May 15 to May 20, with a maximum offer price of HKD 23.30 per share and an entry fee of approximately HKD 2,353.49 for 100 shares [1] - The total expected fundraising amount is HKD 1.086 billion, with a net amount of HKD 881 million, intended for the development, regulatory filing, production, and commercialization of the core product GASTROClearTM [1] Group 2 - The company aims to enhance its "end-to-end" capabilities to capture significant commercial potential within the value chain and to fund ongoing and planned research and development [1] - Key cornerstone investors include Beijing Xunrui Enterprise Management Partnership (Limited Partnership) and Evergreen Gate Limited, which will subscribe to approximately 19.287 million shares at the offer price [1] - MIRXES-B is expected to be listed on the main board on May 23, 2025, with China International Capital Corporation Hong Kong Securities Limited and Jianyin International Financial Limited serving as joint sponsors [1] Group 3 - The company reported net profits of -56.6416 million USD, -69.2250 million USD, and -92.3270 million USD for the years ending December 31, 2022, 2023, and 2024, respectively, with year-on-year changes of -1738.36%, -22.22%, and -33.37% [2]
MIRXES-B(02629.HK) 5月15日—5月20日招股